FDA approves Medicines Co's urinary tract infection drug

[August 30, 2017] (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co's antibacterial drug for patients with complicated urinary tract infections (cUTI).

The drug, Vabomere, was approved to treat adults with cUTI, including pyelonephritis, a potentially life-threatening infection caused by bacteria traveling from the bladder into one or both of the kidneys.

The FDA said it was granting approval of Vabomere to Rempex Pharmaceuticals, a unit of Medicines Co.

Vabomere contains an antibacterial and an inhibitor which deters certain resistance mechanisms used by bacteria.

Shares of Medicines Co were up over 4 percent at $40.46 in after-hours trading on Tuesday.

(Reporting by Manas Mishra in Bengaluru)

[© 2017 Thomson Reuters. All rights reserved.]

Copyright 2017 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.